New UK Government Promises Reform Of NICE - And Value-Added Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE reforms are included in the legislative timetable of the new UK coalition government as the institute continues its work, recommending AstraZeneca's Iressa for lung cancer and rejecting Bayer's Nexavar for liver cancer.
You may also be interested in...
FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow
Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.
FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow
Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.
GSK’s Witty Speaks Further On M&A, Pricing
U.K. pharma giant’s growth will come from a diversified, innovative portfolio of medicines, emerging markets, vaccines, and “bolt-ons.”